Study Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human CD19 targeted DASH CAR-T Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Want to learn more about this trial?
Request More InfoInterventions
Human CD19 Targeted DASH CAR-T Cells InjectionDRUG
Autologous genetically modified anti-CD19 CAR transduced T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The Second Affiliated Hospital of Nanchang University | Nanchang | Jiangxi | China |